PMID- 11157061
OWN - NLM
STAT- MEDLINE
DCOM- 20010607
LR  - 20240213
IS  - 0022-1007 (Print)
IS  - 1540-9538 (Electronic)
IS  - 0022-1007 (Linking)
VI  - 193
IP  - 3
DP  - 2001 Feb 5
TI  - Dendritic cells cross-present latency gene products from Epstein-Barr 
      virus-transformed B cells and expand tumor-reactive CD8(+) killer T cells.
PG  - 405-11
AB  - Dendritic cells (DCs) are not targets for infection by the transforming 
      Epstein-Barr virus (EBV). To test if the adjuvant role of DCs could be harnessed 
      against EBV latency genes by cross-presentation, DCs were allowed to process 
      either autologous or human histocompatibility leukocyte antigen (HLA)-mismatched, 
      transformed, B lymphocyte cell lines (LCLs) that had been subject to apoptotic or 
      necrotic cell death. After phagocytosis of small numbers of either type of dead 
      LCL, which lacked direct immune-stimulatory capacity, DCs could expand CD8(+) T 
      cells capable of killing LCLs that were HLA matched to the DCs. Necrotic 
      EBV-transformed, major histocompatibility complex (MHC) class I-negative LCLs, 
      when presented by DCs, also could elicit responses to MHC class II-negative, 
      EBV-transformed targets that were MHC class I matched to the DCs, confirming 
      efficient cross-presentation of LCL antigens via MHC class I on the DC. Part of 
      this EBV-specific CD8(+) T cell response, in both lytic and interferon gamma 
      secretion assays, was specific for the EBV nuclear antigen (EBNA)3A and latent 
      membrane protein (LMP)2 latency antigens that are known to be expressed at low 
      levels in transformed cells. The induced CD8(+) T cells recognized targets at low 
      doses, 1-10 nM, of peptide. Therefore, the capacity of DCs to cross-present 
      antigens from dead cells extends to the expansion of high affinity T cells 
      specific for viral latency antigens involved in cell transformation.
FAU - Subklewe, M
AU  - Subklewe M
AD  - Laboratory of Cellular Physiology and Immunology, The Rockefeller University, New 
      York, New York 10021, USA.
FAU - Paludan, C
AU  - Paludan C
FAU - Tsang, M L
AU  - Tsang ML
FAU - Mahnke, K
AU  - Mahnke K
FAU - Steinman, R M
AU  - Steinman RM
FAU - Munz, C
AU  - Munz C
LA  - eng
GR  - R01 AI040874/AI/NIAID NIH HHS/United States
GR  - AI40874/AI/NIAID NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Exp Med
JT  - The Journal of experimental medicine
JID - 2985109R
RN  - 0 (EBV-associated membrane antigen, Epstein-Barr virus)
RN  - 0 (Epstein-Barr Virus Nuclear Antigens)
RN  - 0 (Viral Matrix Proteins)
SB  - IM
MH  - Antigen Presentation/*immunology
MH  - Apoptosis/immunology
MH  - B-Lymphocytes
MH  - CD8-Positive T-Lymphocytes/immunology
MH  - Cell Line, Transformed
MH  - Cross Reactions
MH  - Dendritic Cells/*immunology
MH  - Epstein-Barr Virus Nuclear Antigens/*immunology
MH  - Herpesvirus 4, Human/*immunology
MH  - Humans
MH  - Necrosis
MH  - Phagocytosis/immunology
MH  - Viral Matrix Proteins/*immunology
MH  - Virus Latency
PMC - PMC2195925
EDAT- 2001/02/07 11:00
MHDA- 2001/06/08 10:01
PMCR- 2001/08/05
CRDT- 2001/02/07 11:00
PHST- 2001/02/07 11:00 [pubmed]
PHST- 2001/06/08 10:01 [medline]
PHST- 2001/02/07 11:00 [entrez]
PHST- 2001/08/05 00:00 [pmc-release]
AID - 001325 [pii]
AID - 10.1084/jem.193.3.405 [doi]
PST - ppublish
SO  - J Exp Med. 2001 Feb 5;193(3):405-11. doi: 10.1084/jem.193.3.405.